EXECUTIVE ENGAGEMENTS
POOL
463
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
93
Interactions with Platform & by Email
PARTICIPANTS
19
Unique # Participated
VALIDATIONS
8
Responses Validated*
COMPANIES
21
Responses Validated*
* Login for a full stack data experience
DATE
APR 2021
TABLES
210
PAGES
261
EDITION
16
PRICE
USD 5600
CODE
MCP-6464
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
Amid the COVID-19 crisis, the global market for Intravenous (IV) Iron Drugs estimated at US$1.7 Billion in the year 2020, is projected to reach a revised size of US$2.6 Billion by 2027, growing at a CAGR of 6.1% over the analysis period 2020-2027. Ferric Carboxyl Maltose, one of the segments analyzed in the report, is projected to record a 7.4% CAGR and reach US$1.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Iron Sucrose segment is readjusted to a revised 5.4% CAGR for the next 7-year period.
The Intravenous (IV) Iron Drugs market in the U.S. is estimated at US$458.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$554.7 Million by the year 2027 trailing a CAGR of 9.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.2% and 5.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.
In the global Other Product Types segment, USA, Canada, Japan, China and Europe will drive the 4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$338.9 Million in the year 2020 will reach a projected size of US$445.5 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$344.5 Million by the year 2027, while Latin America will expand at a 5.4% CAGR through the analysis period.
SELECT PLAYERS
Allergan Plc.; AMAG Pharmaceuticals Inc.; American Regent Inc.; Luitpold Pharmaceuticals; Pharmacosmos A/S; Sanofi US; Vifor Fresenius Medical Care Renal Pharma; Vifor Pharma Ltd.
SEGMENTS
» Product Type (Ferric Carboxyl Maltose, Iron Sucrose, Other Product Types) » Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Applications)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| Iron Deficiency Anemia (IDA) - An Overview |
| Recent Market Activity |
| Intravenous (IV) Iron Drugs Market - A Quick Primer |
| US and Europe Dominate IV Iron Market |
| Asia-Pacific - The Fastest Growing Market |
| Leading Intravenous Iron Drugs Globally |
| Leading IV Iron Drugs Available in the Market |
| Leading Intravenous Iron Drugs: In a Nutshell |
| Ferinject/Injectafer - The Leading Intravenous Iron Drug Globally |
| Venofer® - Looses Ground to Ferinject |
| Feraheme Obtains Broader Label Approval |
| Feraheme® Obtains FDA Filing Acceptance for Treating All Adult Patients Suffering from IDA |
| Gluconate (Ferrlecit® and Nulecit) |
| Dextran |
| Global Market Leaders |
| 2. FOCUS ON SELECT PLAYERS |
| Allergan Plc. (Ireland) |
| AMAG Pharmaceuticals, Inc. (USA) |
| Daiichi Sankyo, Inc. (USA) |
| Luitpold Pharmaceuticals, Inc. (USA) |
| American Regent, Inc. (USA) |
| Pharmacosmos A/S (Denmark) |
| Sanofi US (USA) |
| Vifor Pharma Ltd. (Switzerland) |
| Vifor Fresenius Medical Care Renal Pharma (Switzerland) |
| 3. MARKET TRENDS & DRIVERS |
| Expanding Pool of ESRD and CKD Patients - The Major Growth Driver for Intravenous (IV) Iron Drugs |
| ESRD Prevalence Statistics: An Opportunity Indicator |
| Increase in Healthcare Spending Bodes Well for Intravenous Iron Drugs Market |
| Dialysis Patients - A Major Market for Intravenous Iron Supplements |
| Ageing Population Drives Demand for IV Iron Drugs |
| Shifting Preference from Oral Iron Drugs to Intravenous Iron Drugs |
| Comparison of Ferrous Salts with IV Iron Therapy |
| Other Chronic Diseases with IDA Offer Prospects for IV Iron Drugs |
| Anemia in Heart Failure - A Market with Huge Potential |
| Chemotherapy Induced Anemia to Promote IV Iron Supplements |
| Correction of IDA in Pregnancy Signals Opportunities |
| Women’s Health - A Key Growth Opportunity |
| Perioperative and Postoperative Anemia - A Niche Market Beckons |
| Adverse Reactions of IV Iron Preparations Raise Concerns |
| Dosing Limitations Plague IV Iron Market |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Ferric Carboxyl Maltose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Ferric Carboxyl Maltose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Ferric Carboxyl Maltose by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Iron Sucrose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Iron Sucrose by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Iron Sucrose by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Chronic Kidney Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Chronic Kidney Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Chronic Kidney Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Inflammatory Bowel Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| SPAIN |
| Spain Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Spain Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Spain 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| Spain Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Spain Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Spain 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| RUSSIA |
| Russia Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Russia Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Russia 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| Russia Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Russia Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Russia 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| AUSTRALIA |
| Australia Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Australia Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Australia 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| Australia Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Australia Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Australia 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| INDIA |
| India Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| India Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| India 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| India Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| India Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| India 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| SOUTH KOREA |
| South Korea Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| South Korea Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| South Korea 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| South Korea Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| South Korea Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| South Korea 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| REST OF ASIA-PACIFIC |
| Rest of Asia-Pacific Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Rest of Asia-Pacific 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| Rest of Asia-Pacific Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Asia-Pacific Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Rest of Asia-Pacific 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| LATIN AMERICA |
| Latin America Current & Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| Latin America Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Latin America 15-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027 |
| Latin America Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Latin America Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Latin America 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| Latin America Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Latin America Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Latin America 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| ARGENTINA |
| Argentina Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Argentina Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Argentina 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| Argentina Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Argentina Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Argentina 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| BRAZIL |
| Brazil Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Brazil Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Brazil 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| Brazil Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Brazil Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Brazil 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| MEXICO |
| Mexico Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Mexico Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Mexico 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| Mexico Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Mexico Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Mexico 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| REST OF LATIN AMERICA |
| Rest of Latin America Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Latin America Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Rest of Latin America 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| Rest of Latin America Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Latin America Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Rest of Latin America 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| MIDDLE EAST |
| Middle East Current & Future Analysis for Intravenous (IV) Iron Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| Middle East Historic Review for Intravenous (IV) Iron Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Middle East 15-Year Perspective for Intravenous (IV) Iron Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027 |
| Middle East Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Middle East Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Middle East 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| Middle East Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Middle East Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Middle East 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| IRAN |
| Iran Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Iran Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Iran 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| Iran Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Iran Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Iran 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| ISRAEL |
| Israel Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Israel Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Israel 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| Israel Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Israel Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Israel 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| SAUDI ARABIA |
| Saudi Arabia Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Saudi Arabia Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Saudi Arabia 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| Saudi Arabia Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Saudi Arabia Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Saudi Arabia 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| UNITED ARAB EMIRATES |
| UAE Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| UAE Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| UAE 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| UAE Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| UAE Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| UAE 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| REST OF MIDDLE EAST |
| Rest of Middle East Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Middle East Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Rest of Middle East 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| Rest of Middle East Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Middle East Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Rest of Middle East 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| AFRICA |
| Africa Current & Future Analysis for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Africa Historic Review for Intravenous (IV) Iron Drugs by Product Type - Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Africa 15-Year Perspective for Intravenous (IV) Iron Drugs by Product Type - Percentage Breakdown of Value Sales for Ferric Carboxyl Maltose, Iron Sucrose and Other Product Types for the Years 2012, 2020 & 2027 |
| Africa Current & Future Analysis for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Africa Historic Review for Intravenous (IV) Iron Drugs by Application - Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Africa 15-Year Perspective for Intravenous (IV) Iron Drugs by Application - Percentage Breakdown of Value Sales for Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer and Other Applications for the Years 2012, 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 21 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com